XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: A meta-analysis

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 3, 2013, Pages 733-740

  Ye, Fanghui ^a   Liu, Zhenfang ^a   Tan, Aihua ^a   Liao, Ming ^a   Mo, Zengnan ^a   Yang, Xiaobo ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Genetic polymorphisms; GSTP1; Oxaliplatin; XRCC1

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE P1; OXALIPLATIN; XRCC1 PROTEIN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; GSTP1 PROTEIN, HUMAN; PLATINUM COMPLEX; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CODON; COLORECTAL CANCER; DRUG EFFICACY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLUTATHIONE TRANSFERASE P1 GENE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; X RAY REPAIR CROSS COMPLEMENTING 1 GENE; COLORECTAL TUMOR; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DNA REPAIR; GENETICS; GENOTYPE; METABOLISM; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVIEW; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA-BINDING PROTEINS; GENETIC MARKERS; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT;

MLCS; MLOWN;

EID: 84875854552     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2067-8     Document Type: Article

References (30)

1. Chai H, Pan J, Zhang X, Shen X, Li H, Zhang K, Yang C, Sheng H, Gao H (2012) ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese. Int J Clin Exp Med 5:186-194
2. Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS (2010) Influence of GSTP1 I105 V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 101:530-535
3. Choi JH, Ahn MJ, Rhim HC, Kim JW, Lee GH, Lee YY, Kim IS (2005) Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. Cancer Res Treat 37:290-293
4. Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ, Iacopetta B (2009) Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 101:998-1004
5. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947 (Pubitemid 30644117)
6. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594-2601 (Pubitemid 41103746)
7. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR (1997) Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18:641-644 (Pubitemid 28132446)
8. Henriette Tanja L, Guchelaar HJ, Gelderblom H (2009) Pharmacogenetics in chemotherapy of colorectal cancer. Best Pract Res Clin Gastroenterol 23:257-273
9. Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, Oh DY, Im SA, Kang GH, Bang YJ (2011) Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol 67:1323-1331
10. Huang MY, Huang ML, Chen MJ, Lu CY, Chen CF, Tsai PC, Chuang SC, Hou MF, Lin SR, Wang JY (2011) Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics 21:18-25
11. Jun L, Haiping Z, Beibei Y (2009) Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss Med Wkly 139:724-728
12. Lamas MJ, Duran G, Balboa E, Bernardez B, Touris M, Vidal Y, Gallardo E, Lopez R, Carracedo A, Barros F (2011) Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics 12:433-442
13. Le Morvan V, Smith D, Laurand A, Brouste V, Bellott R, Soubeyran I, Mathoulin-Pelissier S, Robert J (2007) Determination of ERCC2 Lys751Gln and GSTP1 Ile105 Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8:1693-1703
14. Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW (2010) The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol 66:493-500
15. Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, Ding Y, Feng J, Yu L (2007) Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 15:1049-1053 (Pubitemid 47491460)
16. Liu Y, Chen H, Chen L, Hu C (2012) Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population. Hepatogastroenterology 59:977-980
17. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, Bell DA (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21:551-555 (Pubitemid 30214005)
18. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA (1999) XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59:2557-2561 (Pubitemid 29269097)
19. Lv H, Li Q, Qiu W, Xiang J, Wei H, Liang H, Sui A, Liang J (2012) Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer. Pathol Oncol Res 18:1009-1014
20. Marsh S, McLeod HL (2004) Cancer pharmacogenetics. Br J Cancer 90:8-11 (Pubitemid 38174930)
21. Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Diaz-Rubio E, Gomez-Espana A, Aparicio J, Garcia T, Maestu I, Martinez-Cardus A, Gines A, Guino E (2008) Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 44:1229-1237
22. Martinez-Balibrea E, Manzano JL, Martinez-Cardus A, Moran T, Cirauqui B, Catot S, Taron M, Abad A (2007) Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Oncol Rep 17:637-645
23. Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, Cortes A, Barnadas A, Baiget M (2008) Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 99:1050-1055
24. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25:1247-1254 (Pubitemid 46640571)
25. Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, Lenz HJ (2001) A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21:3075-3079 (Pubitemid 33051178)
26. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936-942 (Pubitemid 34778092)
27. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-354 (Pubitemid 39037082)
28. Suh KW, Kim JH, Kim DY, Kim YB, Lee C, Choi S (2006) Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 13:1379-1385
29. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA (1998) Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19:275-280 (Pubitemid 28375421)
30. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS, Etienne-Grimaldi MC, Wei Q (2011) ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 17:1632-1640